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INTRODUCTION
Since the discovery of testosterone in 1935, it has been a subject 
of great interest for both medical research and in therapy of various 
diseases. Simultaneously, some extra-medical practices have been 
implemented for application of its biological features for improvements 
of appearance, strength and muscle mass [5,6,18,21,23]. Over   
the years, the structure of testosterone was precisely described and 
many of its derivatives were synthesized for the strengthening or 
protracting effects of its biological activity. The group of such drugs 
is known as anabolic-androgenic steroids (AAS) since all of them 
display both anabolic and androgenic effects [10,11,30]. Methods 
of AAS application to athletes of the former German Democratic 
Republic, under the supervision of the Ministry for State Security 
(Stasi), became one of the biggest mystifications and frauds on   
the arena of international sport in the 20th century [8]. 
AAS are the hormones most commonly used for non-medical 
purposes, not only by bodybuilders but also by bodyguards and 
various special units. They are available on the black market often 
without information concerning their type, purity or concentration. 
This brings an additional hazard for the health of the potential takers 
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ABSTRACT: This study was carried out in 40 bodybuilders voluntarily taking supraphysiological doses of anabolic-
androgenic steroids (AAS). Echocardiographic examination of the heart and blood analysis were performed,   
and concentration of AAS in urine was examined. The presence, or absence, of AAS in urine had no influence 
on the echocardiographic parameters of the heart, body mass, body mass index (BMI) and aldosterone level in 
blood plasma. It seems, therefore, that the presence of AAS in urine may confirm heart hypertrophy and overuse 
of AAS, while the absence of AAS in urine does not exclude the cardiological changes occurring as a result of 
taking the drugs. Metabolites detected in urine showed that the intake of 17α-alkyl testosterone derivatives 
caused higher values of left ventricular mass and BMI. However, the level of HDL cholesterol was lower in 
bodybuilders using only 19-nor-testosterone. Elevated level of plasma aldosterone did not differ between   
the two groups. As could be expected, the highest level of AAS in urine was detected in bodybuilders currently 
self-administering the anabolic-androgenic steroids (on cycle). The level of AAS in the urine decreased after 
stopping taking the drugs (off cycle). Refraining from AAS abuse for a period of 1-2 years was associated with 
a significant decrease in aldosterone level in the plasma. The positive correlations found between the blood 
plasma aldosterone, left ventricular mass and BMI lead to the conclusion that large doses of AAS taken by 
bodybuilders would cause extra activation of the renin-angiotensin-aldosterone system.
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since the specimens may contain veterinary medicines or other 
substances not included in the package description [18,30,31]. 
The alarming health disturbances [21,22,23], especially 
cardiological [6,26,32,33], after the use of large doses of anabolic-
androgenic steroids constitute, equally with drug addiction,   
an important medical and social problem [6,9]. 
Previous studies have shown that aldosterone level in the blood 
plasma of bodybuilders correlates with some echocardiographic 
parameters (left ventricular mass) and body mass. Such correlations 
were not found in road cyclists or rowers. On the other hand, these 
sportsmen showed a relation between blood plasma aldosterone level 
and plasma renin activity (PRA) which was not observed in 
bodybuilders. These data suggest that the renin-angiotensin-
aldosterone system may be over-activated in some sportsmen by 
application of large doses of AAS. Such a mechanism would play   
an important role in the development of cardiac pathogenesis reported 
in AAS abusers.
The aim of this study was, therefore, to determine the plasma 
renin activity (PRA), angiotensin-converting enzyme (ACE) and   
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the level of aldosterone in blood plasma in relation to the left 
ventricular echocardiographic parameters of body builders at different 
stages of voluntary application of supra-physiological doses of AAS 
(“on-cycle” and “off-cycle”).
MATERIALS AND METHODS 
The diagnostic examinations and health evaluation of 40 attendants 
of bodybuilding and fitness clubs in Warsaw, usually former athletes, 
were made in the Sport Consulting Clinic by the Institute of Sport in 
Warsaw. Results were confidential and revealed only to the respective 
subjects. Informed consent was obtained. The research project was 
accepted by the local Ethical Commission.
The bodybuilders were divided into 2 subgroups. The first, 
described as “positive”, consisted of 18 subjects in whose urine 
samples steroid metabolites of AAS were found. The second subgroup 
(“negative”) included 22 subjects showing absence of AAS metabolites 
in their urine. In “positive” urine samples, nandrolone metabolites 
in a concentration exceeding the permitted level of 2 ng/ml (for men) 
was found in 8 samples. The average level of nandrolone (19-nor-
testosterone) was 75.7+34.1 ng/ml. The remaining 10 urine samples 
also contained other 17α-alkyl testosterone derivatives.
The group of bodybuilders was further divided into 4 subgroups 
according to the following criteria:
a)   information gathered from the subjects concerning the “cycle” 
phase of the AAS intake;
b) the amount of AAS metabolites detected in the urine samples.
Subgroup I consisted of 9 subjects declaring current consumption 
of an AAS preparation. The test was performed during 7.2±1.2 weeks 
of the cycle. The type of drug voluntarily consumed by the bodybuilders 
was confirmed by the urine samples analysis. Subjects had used the 
AAS for approximately 7 years (total 14 cycles).The AAS doses taken 
in the respective cycles exceeded many times the pharmacological 
recommendations. 
Subgroup II consisted of 9 subjects. They claimed not to have 
taken AAS for 2-3 (or even 12) months but AAS metabolites (mainly 
nandrolone) were detected in their urine. The bodybuilders had used 
AAS for 4 years (6 cycles a year) with the average interval in   
the voluntary administration of about 2.5 months. 
Subgroup III consisted of 14 bodybuilders who took AAS chronically 
for about 10 years. They took approximately 10 (from 5-71) steroid 
cycles, i.e. 120 weeks of its constant application. The intervals in 
this group varied from 3 months to 2 years. The urine analyses 
showed no presence of AAS metabolites (negative samples). 
Subgroup IV consisted of 8 subjects who reported not using   
(2 men) or only occasional use of AAS. Non-AAS metabolites were 
detected in the urine. The period of AAS intake in this group was 
1.4+0.4 years (1.4 cycles) with an interval of 42+10.8 months. 
Subgroup IV was considered as the control subgroup. 
Research methods. The subjects individually reported detailed data 
concerning the state of health, physical activity, and diet, and 
completed a questionnaire regarding history of AAS consumption. 
Next, the medical checking was performed including measurement 
of the resting blood pressure and 12-lead ECG recordings (Marquette 
Hellige CardioSoft).
Echocardiographic examination was conducted using ACUSON 
apparatus. The evaluation of measurements was made by the same 
person. The left ventricular mass (LVM) (g) was calculated according 
to the formula of Devereux: 0.8[1.04(IVSd+LVdD+PWd)
3-
LVdD
3]+0.6g. The following echocardiographic indices were 
calculated: 
-   LVM in transformation to cm of height and assuming the border 
value for an athlete of 1.7g/cm or 170g/m; 
-   heart mass index (g/m
2), as a ratio of left ventricular mass to body 
surface area (MIM) assuming the border value of 143 g/m
2; 
-   left ventricular diastolic dimension (LVDd) (cm);
-   inter-ventricular septal end diastolic dimension (IVSd) (cm) and left 
ventricular posterior wall diastolic dimension (PWd) (cm) with   
the border value of 1.2 cm.
Each subject, unfed, gave blood samples from the ulnar vein to 
three separate test tubes. The first was destined for aldosterone and 
renin plasma activity measurements, the second for evaluation of 
biochemical, hormonal and ACE activity. The third blood sample was 
used for haematological analyses. The subjects collected 24 h urine 
samples, which were used for detection of anabolic steroid metabolites. 
The aldosterone level in the blood plasma was measured according 
to the method described by Ignatowska-Świtalska [17]. The aldosterone 
in plasma was extracted with dichloromethane and analysed in 
duplicate by the RIA method using aldosterone antibodies (SIGMA), 
tritiated aldosterone (ELKABE-Amersham) and standard aldosterone 
(Peninsula). The antibodies showed cross-reaction with cortisone, 
corticosterone and deoxycortone at a level lower than 0.001%. 
Variability of the method was 8% for intra-serial and 12% for inter-
serial comparison, with the reference value of 7.8+2.4 (3-15) ng/dl.
The plasma renin activity was determined with the RIA method 
and Immunotech kit (reference values: 1.7+1.1 (0.3-3.5) ng/ml/min). 
The ACE activity was evaluated by the Liberman method [20].   
The reference value was set at 28.1+3.9 (0.3-3.5) mU/ml.
Levels of testosterone (reference value: 9-38 nmol/l) and luteinizing 
hormone (LH) (reference: 3-9 U/L) were measured with immuno-
enzymatic methods by ELISA (IBL) and MicroRider3.
The identification of anabolic steroid metabolites was carried out 
using a gas chromatograph connected with a gas spectrometer   
(GC/MS-5973N, Agilent). The measurements of the AAS metabolites 
followed the procedures implemented by the Medical Commission of 
the International Olympic Committee (Medical Code - Appendix B).
The following biochemical parameters were measured in   
the blood (with reference values given in brackets): total cholesterol 
(120-200 mg/dl), HDL cholesterol (over 35 mg/dl), LDL cholesterol 
(up to 135 mg/dl), triglycerides (35-135 mg/dl) as well as the 
activity of enzymes: creatine CK (up to 190 U/L), asparagine 
transaminase GOT (up to 37 U/L), alanine transaminase GPT (up 
to 41 U/L), γ-glutamyl-transferase (γ-GT, 11-50 U/L), level of   
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creatinine (53-97 μmol/l), urea (1.7-8.3 mmol/l), total bilirubin 
(up to 18.8 μmol/l) and glucose (3.9-6.1 mmol/l). The biochemistry 
of blood was evaluated with the ARCO apparatus (Italy) and 
calorimetric method (by the selective length of waves from 340 to 
630 nm).
Haematological analyses were performed in a SWELAB Auto 
Counter 920E (SWEDEN) through the conductometric method,   
e.g. red blood cell count (RBC 4.7-6.1 T/L), haematocrit (HT 42-52%), 
haemoglobin concentration (HGB 140-180 G/L), platelet count (PLT 
150-400 10º/L), and white blood cell count (WBC 4.5-10.1 G/L). 
Electrolytes in the blood plasma, such as sodium (136-147 mmol/l), 
potassium (3.6-5.0 mmol/L), magnesium (0.53-0.67 mmol/L) and 
calcium (1.13-1.32 mmol/L), were determined by the ionic selector 
NOVA-8 PROFUTURA Analyser (USA). Levels of creatinine, sodium 
and potassium in plasma as well as their 24 h excretion were measured. 
The respective reference values were as follows: sodium – 150-250 
mmol/24; potassium – up to 100 mmol/24.
Statistical analyses. Statistical data evaluation by means of ANOVA 
was performed with the STATISTICA StatSoft program. Significance 
of differences between respective groups was estimated with   
the Kruskal-Wallis test or Mann-Whitney U test for two independent 
groups. The coefficients of correlation inside groups were evaluated 
with the non-parametric Spearman rank test. The statistical 
significance of differences was set at the level p<0.05.
RESULTS 
The results obtained for 18 “positive” and 22 “negative” bodybuilders 
are presented in Table 1. A significant lowering of creatinine kinase 
activity, red blood cells (RBC), haematocrit (HT) and haemoglobin 
(HGB) was observed only in the “negative” subgroup of subjects.
Measured variable
Bodybuilders Bodybuilders 
Significance of differences
“positive” “negative”
Number of subjects 18 22 p<
Age (years) 26.5±1.6 31.3±1.8 0.006
Body mass (kg) 93.9±2.8 91.7±2.5 NS
Height (cm) 175.2±1.1 177.4±1.2 NS
Body mass index BMI (g) 30.6±2.9 29.2±3.0 NS
Body surface area BSA (m
2) 2.06±0.16 2.09±0.15 NS
Left ventricle of the heart mass (g) 266.0±16.0 254.0±9.5 NS
Left ventricle of the heart mass (g/cm) 1.50±0.09 1.40±0.05 NS
Left ventricle mass /BSA (g/m
2) 122.8±5.7 121.0±3.7 NS
LVDd (cm) 5.5±0.1 5.4±0.1 NS
IVSd (cm) 1.16±0.03 1.13±0.02 NS
PWd (cm) 1.15±0.02 1.13±0.02 NS
Plasma renin activity (u/ml/h) 2.8±0.3 2.5±0.4 NS
ACE (mU/ml) 31.1±1.8 29.4±1.9 NS
ALDO (ng/dl) 11.6±1.2 8.5±0.9 NS
ALDO/ARO Index 8.3±1.7 5.9±1.1 NS
Systolic pressure (mmHg)  126.6±1.6 128±2.4 NS
Diastolic pressure (mmHg)  82.2±1.8 80.0±1.5 NS
Creatine kinase CK (U/L) 1058±341 358±58 0.04
Asparagine transferase GOT (U/L) 60.1±9.1 39.8±3.3 NS
HDL cholesterol (mg/dl) 32.8±3.1 34.5±2.7  NS
Luteinizing hormone LH 3.9±5.8 3.8±4.8 NS
Sodium in serum ( mmol/l)  146.3±0.4 146.1±0.4 NS
Potassium in serum (mmol/l) 4.4±0.1 4.1±0.1 0.047
Magnesium in serum (mmol/l)  0.52±0.10 0.52±0.06 NS
Calcium in serum (mmol/l) 1.24±0.01 1.24±0.01 NS
Red blood cells (RBC T/L) 5.38±0.08 4.90±0.08 0.0027
Haematocrit (HT) 47.4±0.7 44.9±0.7 0.01
Haemoglobin concentration (HGB – g/L) 170.7±2.1 160.1±2.1 0.009
TABLE 1. ANTHROPOMETRIC DATA AND SELECTED ECHOCARDIOGRAPHIC PARAMETERS OF THE LEFT VENTRICLE OF THE HEART, 
BLOOD  PRESSURE,  PLASMA  RENIN  ACTIVITY  (PRA),  ACE  ACTIVITY  AND  LEVELS  OF  BLOOD  PLASMA  ALDOSTERONE  (ALDO)   
IN SUBGROUPS OF “POSITIVE” AND “NEGATIVE” BODYBUILDERS (MEAN±SD).
Legend: p<0.05* Significantly different, NS – non significant, Abbreviations: HMI – heart mass index (g/m
2); LVDd – left ventricular diastolic dimension, IVSd – interventricular 
septum diastolic dimension, PWd – left ventricular posterior wall diastolic dimension, ALDO – aldosterone; PRA – plasma renin activity; ACE – angiotensin-converting enzyme 
activity.
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Table 2 shows the values of Spearman’s correlation coefficient R 
regarding the aldosterone and echocardiographic parameters 
measured in the whole group of bodybuilders and in both subgroups 
separately. The whole group of bodybuilders exhibited a significant 
relation between the plasma aldosterone level and the body mass 
index, left ventricular mass indexed to height in centimetres, inter-
ventricular septal end diastolic dimension (IVSd) and ACE activity. 
Correlation coefficients in the “positive” and “negative” subgroup 
were not statistically significant. 
Data presented in Table 3 show that subjects whose urine 
contained only the nandrolone metabolite (19-NA) had lower values 
of body mass, left ventricular mass of the heart, heart muscle mass 
Measured variable
Bodybuilders
Whole group “positive” “negative”
n=40 n=18 n=22
ALDO (ng/dl) ALDO (ng/dl) ALDO (ng/dl)
Body mass (kg) 0.307 (0.053) 0.25 (NS) 0.44 (p<0.03)
Body mass index BMI (g/m) 0.31 (p<0.045) 0.53 (p<0.02) 0.18 (NS)
Body surface area BSA (g/m
2) 0.27 (NS) 0.29 (NS) 0.37 (NS)
Mass LK (g)* 0.33 (p<0.03) 0.35 (NS) 0.36 (NS)
Mass LK/cm  0.33 (p<0.03) 0.43 (NS) 0.28 (NS)
HMI(g/m
2) 0.228 (NS) 0.34 (NS) 0.16 (NS)
LVDd (cm) 0.31 (0.051) 0.26 (NS) 0.39 (NS)
IVSd (cm) 0.33 (p<0.03) 0.50 (p<0.03) 0.8 (NS)
PWd (cm) 0.25 (NS) 0.41 (NS) 0.8 (NS)
ARO (ng/ml/h) 0.17 (NS) 0.1 (NS) 0.29 (NS)
ACE (mU/ml)  0.31 (0.047) 0.24 (NS) 0.27 (NS)
Systolic pressure (mmHg) -0.10 (NS) -0.24 (NS) -0.005 (NS)
Diastolic pressure (mmHg) -0.15 (NS) -0.19 (NS) 0.19 (NS)
Legend and abbreviations – see Table 1
TABLE 2. INTRA-GROUP COMPARISON OF BODYBUILDERS. R – CORRELATION COEFFICIENT BETWEEN PLASMA ALDOSTERONE 
LEVELS FOR THE WHOLE GROUP , “POSITIVE” AND “NEGATIVE” BODYBUILDERS AND SELECTED ECHOCARDIOGRAPHIC PARAMETERS 
OF THE LEFT VENTRICLE OF THE HEART, BODY MASS, BMI, BSA, PRA, ACE AND SYSTOLIC AND DIASTOLIC BLOOD PRESSURE.
TABLE 3. METABOLITES OF ANABOLIC-ANDROGENIC-STEROIDS (AAS) IN BODYBUILDERS.
Measured variable
Bodybuilders  Bodybuilders  Bodybuilders
Significance of 
differences
(p<)*
“positive” “positive” “negative”
(AAS found  
in urine)
 (nandrolone found  
in urine)
(no AAS metabolites  
in urine) 
Number of subjects 10 8 8 1 vs 2 1 vs 3 2 vs 3
Age (years) 29.3±2.2 23.1±1.9 27.3±2.8 0.008 NS NS
Body mass (kg) 98.4±3.8 88.5±3.5 80.7±3.1 0.01 0.0007 NS
Body mass index BMI 31.1±1.1 29.9±0.8 26.5±0.8 NS 0.001 NS
Left ventricle mass (g)  291.5±22.5 234.0±18.2 215±14.8 0.01 0.001 NS
Left ventricle mass (g/cm) 1.65±0.13 1.34±0.10 1.20±0.08 0.03 0.002 NS
Left ventricle mass /BSA (g/m
2) 130.0±8.5 112.0±6.4 110.0±6.2 0.03 0.02 NS
LVDd (cm) 5.60±0.14 5.40±0.15 5.20±0.14 NS 0.037 NS
IVSd (cm) 1.22±0.04 1.10±0.05 1.03±0.03 0.03 0.0002 NS
PWd (cm) 1.20±0.03 1.10±0.03 1.05±0.02 0.006 0.0003 NS
ARO (ng/ml/h) 1.97±0.36 2.43±0.61 1.90±0.55 NS NS NS
ALDO (ng/dl) 11.6±1.7 11.5±1.7 7.2±1.8 NS 0.03 NS
Creatine kinase (U/L) 1092±63 10315±55 262±362 NS 0.002 NS
HDL-cholesterol mg/dl 26.0±3.9 41.2±2.9 34.0±4.4 0.014 NS NS
Red blood cells (RBC- T/L) 5.37±0.10 5.41±0.10 5.00±0.15 NS 0.02 NS
Haemoglobin (HGB G/L) 170.9±2.8 168.3±3.8 160.0±3.7 NS 0.007 NS
Potassium in urine mmol/l 59.9±6.3 42.2±11.3 41.5±8.7 0.02 0.03 NS
Potassium mmol/24h in urine 121.6±15.5 80.4±19.6 71.4±14.9 0.03 0.004 NS
Legend and abbreviations – see Table 1 
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index and HDL cholesterol level in comparison to the subgroup where 
other 17α-alkyl testosterone derivatives were found. The potassium 
level in urine and its 24 h excretion were statistically higher in subjects 
taking other 17α-alkyl testosterone derivatives.
Table 4 presents a comparison of the results of 4 chosen tests 
obtained by 4 subgroups of bodybuilders. The body mass of subjects 
who currently take AAS was statistically higher in relation to subgroup 
2 but did not differ from subgroup 3 (subjects using AAS systematically 
but not taking them at present and having the urine samples clear). 
The body mass index (BMI), body surface area (BSA), left ventricular 
mass indexed to height in cm (LVM/cm) and to the body surface area 
(MIM), left ventricular diastolic dimension (LVDd), thickness of   
the diastolic inter-ventricular septum (IVSd) and left posterior wall 
in diastole (PWd) were similar. These values were significantly higher 
in subgroup 1 in comparison to subgroups 2 and 4. The aldosterone 
level was higher in subgroup 1 than in subgroup 4. The plasma renin 
activity (PRA), ACE values and arterial diastolic and systolic blood 
pressure did not differ between the subgroups. The HDL cholesterol 
level and the luteinizing hormone (LH) level were statistically lower 
in subjects currently taking AAS (subgroup 1) in relation to other 
subgroups. Asparagine transaminase (GOT) activity was statistically 
higher in subgroup 1. Although the excretion of sodium and potassium 
in urine and the Na/K index were within the accepted norms, 
subgroup 1 showed elevated 24 h kaliuresis. 
Subgroup
Bodybuilders Bodybuilders
Significance of differences “positive” “negative”
1 2 3 4
Number of subjects N=9 N=9 N=14 N=8 1 vs 2
2 vs 3
1 vs 3
2 vs 4
1 vs 4
3 vs 4
Age (years) 29.9±2.5 23.3±2.5 32.6±2.0 27.3±2.8
NS NS NS
0.003 NS 0.00039
Body mass (kg) 103.5±2.8 84.4±2.8 96.9±2.2 80.7±3.1
0.001 NS 0.00015
0.0008 NS 0.00001
Height (cm) 175.5±1.7 174.8±2.1 178.7±1.5 175.1±1.5
NS 0.36 NS
0.009 NS 0.00036
Body mass index BMI (kg/m
2) 32.9±0.7 28.2±0.7 30.6±0.6 26.5±0.8
0.0018 NS 0.00001
0.0001 NS 0.00001
Body surface area (m
2) 2.20±0.04 1.90±0.04 2.10±0.03 1.90±0.04
0.0018 NS 0.015
0.0001 NS 0.000007
Left ventricle mass (g) 319±13 212±13 273±11 215±15
0.00024 NS 0.0001
0.00025 NS 0.00001
Left ventricle mass (g/cm) 1.80±0.07 1.20±0.07 1.50±0.06 1.20±0.08
0.00004 NS 0.00003
0.0002 NS 0.00001
Left ventricle mass/ BSA (g/m
2) 140.9±5.4 104.8±5.4 128.6±4.3 110.0±6.2
0.00025 NS 0.0009
0.00008 NS 0.0001
LVDd (cm) 5.80±0.12 5.20±0.12 5.50±0.09 5.20±0.14
0.03 NS 0.008
0.02 NS 0.0002
IVSd (cm) 1.30±0.03 1.05±0.03 1.20±0.02 1.03±0.03
0.002 NS 0.00003
0.0015 NS 0.00001
PWd (cm) 1.23±0.02 1.07±0.02 1.17±0.02 1.05±0.02
0.023 NS 0.00016
0.0005 NS 0.00000
Aldosterone (ng/dl) 13.6±1.6 9.8±1.6 9.2±1.3 7.2±1.8
NS NS 0.037
NS NS NS
Cholesterol HDL (mg/dl) 23.2±3.8 42.3±3.8 34.8±3.1 34.0±4.4
0.001 0.02 0.048
NS NS NS
LH in serum (mU/ml) 0.9±1.8 5.6±1.8 3.9±1.5 4.4±2.1
0.026 0.004 0.01
NS NS NS
Creatine kinase activity CK (U/L) 1306±337 810±337 421±271 262±362
0.001 0.004 0.004
NS NS NS
Asparagine transferase activity GOT (U/L) 74.0±9.1 46.2±9.1 43.3±7.4 35.1±10.2
NS 0.02 0.029
NS NS 0.023
Alanine transferase activity GPT (U/L) 88.1±24.7 37.1±7.3 55.0±10.9 37.3±6.6
NS NS NS
0.026 NS 0.001
Legend and abbreviations – see Table 1
TABLE 4. MORPHOLOGICAL, BIOCHEMICAL AND HAEMATOLOGICAL RESULTS FOR 4 SUBGROUPS OF BODYBUILDERS. 
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DISCUSSION 
In spite of the large amount of conducted research [4,13,14,31, 32] 
the pathogenesis of health disorders connected with the use of 
large doses of androgens [6,8,9,10,15,22,29] remains unclear. 
The destructive effects of intake of large amounts of steroids in 
animals have not, up to now, been confirmed in humans [2]. 
Recent clinical and experimental studies proved that the increased 
activity of the renin-angiotensin-aldosterone system (RAAS) plays   
an important role in the pathogenesis of cardiological diseases: cardiac 
infarctions, arterial hypertension and circulatory failure. Hence,   
it may be assumed that over-activation of the RAAS may also be   
a factor eliciting the changes in the cardiovascular system observed 
in subjects taking AAS for doping purposes [25,28,35]. 
The pathogenesis of cardiological changes and many tragic cases 
resulting from AAS abuse could depend on the strong stimulation of 
the RAAS and enforced effects of the tissue aldosterone operation 
[4,6,26,30,32,33]. A raised level of aldosterone is considered to be 
an independent risk factor of occurrence of cardiological illnesses, 
independently of increased blood pressure [25,28,35]. 
The results of the present study showed that the presence of AAS 
metabolites in urine may be an illusive criterion of recognition of   
the cardiological changes in the abuser’s body. Individuals who have 
been taking AAS chronically and have negative test results for AAS 
metabolites in urine often show a long-term increase of aldosterone 
level in plasma associated with abnormal echocardiographic 
parameters of the heart. Increased levels of aldosterone in plasma, 
echocardiographic heart dimensions, body mass and BMI, which 
last for much longer than the presence of metabolites of AAS in urine, 
are probably the basis for AAS application as a doping agent. In this 
context heart muscle hypertrophy would be an accepted factor of 
increased risk of heart diseases [3,7,32,35]. 
Molecular mechanisms of heart hypertrophy have been a subject 
of various studies [3,7,9,27,34]. It is generally believed that   
the so-called “athlete’s heart”, where the heart muscle hypertrophy 
is the effect of adaptation to long-term physical effort, is a physiological 
phenomenon. However, during a complex process of heart and skeletal 
muscle hypertrophy in subjects taking large doses of AAS and 
consuming a diet rich in protein, the heart and skeletal muscles fibres 
grow, as a consequence of the activation of satellite cells (hyperplasia) 
in proportion to the applied dose of AAS [16,27]. 
Decreased HDL cholesterol level and increased creatine kinase 
activity were the common biochemical changes observed in the group 
of bodybuilders who currently applied AAS [8]. As has been reported, 
the anabolic-androgen steroids markedly lower the HDL cholesterol 
fractions [1,10,12,15,19,24]. The results of the present study 
showed that the 17α-alkyl testosterone derivatives lowered the HDL 
cholesterol level in the serum more strongly than in subjects who 
take nandrolone. As a consequence, the type of applied AAS should 
be regarded as a discrimination factor enabling verification of subjects 
who are using and not using AAS [12,13,14,15,19,34].
The results of the present study confirm the hypothesis that large 
doses of AAS may act through the molecular mechanism of activation 
of androgen receptors (slow genomic or fast non-genomic), cell 
membrane receptors and the cascade of secondary transmitters as 
well as through stimulation of many other systems including   
the RAAS [4,5,30]. It seems that the activation of the RAAS was 
one of the sources of increased synthesis for the heart muscle and 
skeletal muscle hypertrophy. The cessation of AAS intake diminished 
the activity of the RAAS very slowly. The process of recovery of plasma 
level of aldosterone in subjects abusing AAS needs further studies. 
It seems that the increased expression of the RAAS receptors, 
increased activity of angiotensin II and the synthesis of aldosterone 
constitute an important mechanism of anabolic steroids’ effects in 
the pathogenesis of heart and skeletal muscle hypertrophy. Excessive 
and long-term stimulation of this system may enlarge the pathological 
changes in people who take large doses of AAS [28,33,35]. 
CONCLUSIONS 
•   This study showed that non-medical application of AAS caused 
an increase in concentration of plasma aldosterone, changes in 
echocardiographic parameters of the heart, and increases in body 
mass and body mass index. These changes attained the highest 
values in bodybuilders currently taking AAS (on cycle) but they 
were also present during the period of cessation in AAS application 
(off cycle).
•   The presence of AAS metabolites in the urine of bodybuilders 
may confirm the association between AAS abuse and heart muscle 
hypertrophy. On the other hand, negative results of the AAS 
doping test do not exclude cardiovascular changes occurring as 
a consequence of AAS use.
•   The derivatives of 17α-alkyl testosterone (e.g. methandienone) 
decreased the level of HDL cholesterol in the blood while 
nandrolone did not show such an effect.
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